Vapotherm Blog

[FELIX-1 White Paper] – Computational Fluid Dynamic Modelling of Particle Capture: Possible Use of a Modified Face-Tent as a Facial Scavenger

Aerosol generating procedures (AGPs) present a substantial clinical challenge during any clinical interaction, much less during a global viral pandemic. Control of AGPs during respiratory therapy procedures is important. Various methods of mitigation have been proposed for non-invasive ventilatory support.

FELIX-1: Creating a Localized Area of Negative Pressure for COVID-19 Patients

Even before COVID-19 became a truly global pandemic, it became clear that protecting healthcare workers (HCWs) from infection was crucial. Many major health organizations, like the Centers for Disease Control and Prevention (CDC), the World Health Organization (WHO).

Velocity – Ep 7 – Respiratory Directors Share COVID-19 Experiences

Shelly Brown from Arkansas, Vernon Druses from New York, and Lenny Nyangwara from Maryland are all Respiratory Department leaders.
They share their experiences on how the coronavirus pandemic has impacted their hospitals and clinical practice and discuss treating the respiratory symptoms associated with COVID-19.

Velocity – Ep 6 – An ED Physician and COVID-19 Patient (Part 2)

Dr. Louis Philip Rotkowitz is an ER doctor out of Queens, NYC. Like so many other health care professionals, he would find himself fighting COVID-19 as a patient. In this episode, Dr. Rotkowitz reflects on his experience in a conversation with fellow ER physician, Dr. Kirk Hinkley.

Joe Army

We’re here for you. A COVID-19 update from CEO Joe Army

The pandemic isn’t over. Vapotherm CEO Joe Army brings you to our Exeter, NH headquarters to share what we’ve been up to to best support you and your patients.

Thinking Outside the Mask with COPD

Clinicians familiar with literature on Vapotherm high velocity therapy are already aware that Vapotherm therapy has been clinically proven to be comparable to noninvasive positive pressure ventilation (NiPPV) when treating respiratory distress in spontaneously breathing patients. In a 2018 randomized, controlled, multi-center noninferiority trial, Doshi and colleagues compared the efficacy of a mask-free form of NIV (Vapotherm high velocity therapy) to an established respiratory support modality (NiPPV).

New Analysis Suggests Vapotherm High Velocity Therapy May Be as Effective as Noninvasive Positive Pressure Ventilation (NiPPV) Among Studied Hypercapnic Patients

In April 2020, Doshi and colleagues published the results of a subgroup analysis in Heart & Lung titled “The ventilatory effect of high velocity nasal insufflation compared to non-invasive positive-pressure ventilation in the treatment of hypercapneic respiratory failure: a subgroup analysis.” The analyses examined the hypercapnic sub-population of a multi-center, randomized, controlled, non-inferiority trial.

Velocity – Ep 5 – An ED Physician and COVID-19 Patient

Dr. Louis Philip Rotkowitz is an ER doctor out of Queens, NYC. Like so many other health care professionals, he would find himself fighting COVID-19 as a patient. In this episode, Dr. Rotkowitz reflects on his experience in a conversation with fellow ER physician, Dr. Kirk Hinkley.

COVID-19 Best Practices with Vapotherm High Velocity Therapy

The last weeks have proven to be a steep learning curve for COVID-19 respiratory symptom management. Here is a quick list of best practices for Vapotherm high velocity therapy. Remember: No Need to Intubate Everyone When COVID-19 first broke out, the initial course of symptom management across many locales was early intubation.

COPD Patients and COVID-19 – Understanding the Scope of High Velocity Therapy

We’ve known that people with underlying conditions are at greater risk for worse COVID-19 outcomes. Thanks to the research of Leung and colleagues, we now better understand some of the mechanisms that may be exacerbating the outcomes for smokers and COPDers who contract COVID-19.